Lymphome de Burkitt avec un syndrome de lyse tumorale actif ou imminent au moment du diagnostic: LDH > 2× LSN,...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

ID	`RF-BURKITT-EMERGENCY-TLS`
Type	Signal d’alerte
État	reviewed 2026-04-27 \| pending_clinical_signoff
Maladies	`DIS-BURKITT`
Sources	`SRC-ESMO-BURKITT-2024` `SRC-NCCN-BCELL-2025`

Origine du drapeau rouge

Définition	Burkitt lymphoma with active or imminent tumor lysis syndrome at diagnosis: LDH >2× ULN, uric acid >7.5 mg/dL, hyperkalemia, hyperphosphatemia, hypocalcemia, AKI — Burkitt is the textbook TLS disease (doubling time 24-48 h)
Direction clinique	en attente
Catégorie	dysfonction d'organe
Algorithme de décalage	ALGO-BURKITT-1L

Logique de déclenchement

{
  "any_of": [
    {
      "comparator": ">",
      "finding": "ldh_ulnratio",
      "threshold": 2
    },
    {
      "comparator": ">",
      "finding": "uric_acid_mg_dl",
      "threshold": 7.5
    },
    {
      "comparator": ">",
      "finding": "potassium_mmol_l",
      "threshold": 5.5
    },
    {
      "comparator": ">",
      "finding": "phosphate_mg_dl",
      "threshold": 4.5
    },
    {
      "comparator": ">",
      "finding": "creatinine_mg_dl",
      "threshold": 1.5
    },
    {
      "finding": "tls_active",
      "value": true
    }
  ],
  "type": "composite"
}

Notes

Per NCCN Burkitt v.X.2025 §BURK-A: rasburicase mandatory for Burkitt pre-cycle-1; allopurinol insufficient for high-risk. ESMO-Burkitt 2024 echoes: rasburicase 0.2 mg/kg IV daily ×3-5 days, IV hydration 3 L/m²/day. Burkitt has highest TLS incidence among lymphomas (>30% high-risk). Direction HOLD on regimen start until uric acid <7.5, potassium <5.0, phosphate <4.5, creatinine baseline restored. Priority 10. Note this is a Burkitt-specific complement to RF-UNIVERSAL-TLS-RISK (which is intensify, surfaces supportive care without holding); this disease- specific HOLD is needed because Burkitt cycle 1 reduction-phase (COP/cyclophosphamide-vincristine-prednisone) sits between universal TLS-prophylaxis and definitive induction. STUB — requires clinical co-lead signoff.

Utilisé par

No reverse references found in the YAML corpus.